Alessandro Di Federico

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile

0.258Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100759

Top 59%

0.258DataRank

Top 59%4 citations

Andrea Arfè, Biagio Ricciuti, Andréanne Gagné, Lynette M. Sholl, Alessandro Di Federico +19 more

Papers

Driven by 18 papers — median percentile 41. Top paper: “Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review”.

Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review

Lung Cancer: Targets and Therapy(2023)10.2147/lctt.s388047

N/A

0.776DataRank · unranked

19 citations

Paola Valeria Marchese, Chiara Deiana, Chiara Casadio, Linda Galvani, Alessandro Di Federico +2 more

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1207

N/A

0.542DataRank · unranked

36 citations

Biagio Ricciuti, Chaitanya Bandlamudi, Daniel M. Muldoon, Hira Rizvi, Arielle Elkrief +23 more

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

Nature Communications(2023)10.1038/s41467-023-39874-8

N/A

0.515DataRank · unranked

30 citations

Biagio Ricciuti, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti +13 more

Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors

Annals of Oncology(2024)10.1016/j.annonc.2024.11.014

N/A

0.489DataRank · unranked

25 citations

Lingzhi Hong, Arielle Elkrief, Rohit Thummalapalli, Alissa J. Cooper, Biagio Ricciuti +43 more

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-006994

N/A

0.416DataRank · unranked

15 citations

Joao V. Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul +16 more

Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.07.121

N/A

0.373DataRank · unranked

11 citations

Alessandro Di Federico, Bolun Liu, Alissa J. Cooper, Joao V. Alessi, Phoebe Clark +25 more

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1735

N/A

0.345DataRank · unranked

9 citations

Hui Li, Alessandro Di Federico, Jia Wu, Hong Chen, Eleonora Gariazzo +26 more

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007618

N/A

0.330DataRank · unranked

8 citations

Adam Price, Allison L. Richards, Biagio Ricciuti, Xinan Wang, Arielle Elkrief +14 more

Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib

JCO Precision Oncology(2023)10.1200/po.23.00295

N/A

0.315DataRank · unranked

5 citations

Biagio Ricciuti, Guilherme Harada, Matteo Repetto, Melissa Gildenberg, Ankit Singh +16 more

Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC

Nature Communications(2025)10.1038/s41467-025-61823-w

N/A

0.312DataRank · unranked

7 citations

Qasem Al-Tashi, Lingzhi Hong, Vivek Verma, Wentao Li, Daniel Boiarsky +32 more

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2990

N/A

0.312DataRank · unranked

7 citations

Rohit Thummalapalli, Stephanie Alden, Biagio Ricciuti, Joao V. Alessi, Arielle Elkrief +18 more

Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.03.045

N/A

0.292DataRank · unranked

6 citations

Federica Pecci, Biagio Ricciuti, Felix H. Gottlieb, Francesco Facchinetti, Guilherme Harada +21 more

Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100759

Top 59%

0.258DataRank

Top 59%4 citations

Andrea Arfè, Biagio Ricciuti, Andréanne Gagné, Lynette M. Sholl, Alessandro Di Federico +19 more

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers

Research Square(2024)10.21203/rs.3.rs-3782958/v1

N/A

0.104DataRank · unranked

1 citations

Taek-Chin Cheong, Ahram Jang, Qi Wang, Giulia C. Leonardi, Biagio Ricciuti +6 more

Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-012205

N/A

0.104DataRank · unranked

1 citations

Biagio Ricciuti, Arielle Elkrief, Joao V Alessi, Alessandro Di Federico, Federica Pecci +11 more

Impact of TMB, PD-L1 expression, and pneumonitis on outcomes to chemoradiation and durvalumab in unresectable stage III non-small cell lung cancers

Research Square(2022)10.21203/rs.3.rs-2273813/v1

N/A

0DataRank · unranked

0 citations

Biagio Ricciuti, Xinan Wang, Giuseppe Lamberti, Arielle Elkrief, Federica Pecci +12 more

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers

Nature Communications(2024)10.1038/s41467-024-49499-0

N/A

0DataRank · unranked

13 citations

Ahram Jang, Qi Wang, Giulia C. Leonardi, Biagio Ricciuti, Joao V. Alessi +6 more

Efficacy of PD-(L)1 blockade monotherapy compared to PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study

medRxiv(2022)10.1101/2022.12.05.22283131

N/A

0DataRank · unranked

0 citations

Joao M. Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul +16 more

Alessandro Di Federico

Indexed papers

Top data-sharing exemplar

Papers